{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:18:07Z","timestamp":1787876287408,"version":"build-2784847793"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04457-1","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:52:59Z","timestamp":1781776379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies"],"prefix":"10.1007","volume":"75","clinical-trial-number":[{"clinical-trial-number":"nct02908906","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Piotr","family":"Rutkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz M.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitana","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Thistlethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Loffredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Akapeme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jonathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Girvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalaka","family":"Hampras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hellemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iurie","family":"Bulat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"4457_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","volume":"23","author":"Q Liu","year":"2024","unstructured":"Liu Q, Guan Y, Li S (2024) Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers\u202f: the \u201call-around warrior\u201d in immunotherapy. Mol Cancer 23:183. https:\/\/doi.org\/10.1186\/s12943-024-02095-8","journal-title":"Mol Cancer"},{"key":"4457_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-022-04415-5","volume":"89","author":"N DeAngelis","year":"2022","unstructured":"DeAngelis N, Ferrante C, Powers G et al (2022) Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemother Pharmacol 89:515\u2013527. https:\/\/doi.org\/10.1007\/s00280-022-04415-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"4457_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00280-022-04414-6","volume":"89","author":"E Felip","year":"2022","unstructured":"Felip E, Moreno V, Morgensztern D et al (2022) First-in-human, open-label, phase 1\/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol 89:499\u2013514. https:\/\/doi.org\/10.1007\/s00280-022-04414-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"4457_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/CAD.0000000000000648","volume":"29","author":"MG Franken","year":"2018","unstructured":"Franken MG, Kanters TA, Coenen JL, de Jong P, Koene HR, Lugtenburg PJ, Jager A, Uyl-de Groot CA (2018) Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anticancer Drugs 29:791\u2013801. https:\/\/doi.org\/10.1097\/CAD.0000000000000648","journal-title":"Anticancer Drugs"},{"key":"4457_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2147\/PPA.S87271","volume":"9","author":"JF Jin","year":"2015","unstructured":"Jin JF, Zhu LL, Chen M, Xu HM, Wang HF, Feng XQ, Zhu XP, Zhou Q (2015) The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence 9:923\u2013942. https:\/\/doi.org\/10.2147\/PPA.S87271","journal-title":"Patient Prefer Adherence"},{"key":"4457_CR6","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","volume":"107","author":"SZ Usmani","year":"2022","unstructured":"Usmani SZ, Nahi H, Legiec W et al (2022) Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica 107:2408\u20132417. https:\/\/doi.org\/10.3324\/haematol.2021.279459","journal-title":"Haematologica"},{"key":"4457_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"4457_CR8","unstructured":"KEYTRUDA (pembrolizumab). Prescribing information. Merck & Co., Inc.; 2025. Accessed August 29, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125514s178lbl.pdf."},{"key":"4457_CR9","unstructured":"OPDIVO (nivolumab). Prescribing information. Bristol Myers Squibb; 2025. Accessed August 29, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125554s131lbl.pdf."},{"key":"4457_CR10","unstructured":"OPDIVO Qvantig (nivolumab and hyaluronidase-nvhy). Prescribing information. Bristol Myers Squibb; 2025. Accessed August 29, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761381s008lbl.pdf."},{"key":"4457_CR11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","volume":"36","author":"E Felip","year":"2025","unstructured":"Felip E, Rojas CI, Schenker M et al (2025) Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A\u2013D77 trial. Ann Oncol 36:775\u2013785. https:\/\/doi.org\/10.1016\/j.annonc.2025.03.012","journal-title":"Ann Oncol"},{"key":"4457_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.annonc.2024.09.002","volume":"36","author":"L Albiges","year":"2025","unstructured":"Albiges L, Bourlon MT, Chacon M et al (2025) Subcutaneous versus intravenous nivolumab for renal cell carcinoma. Ann Oncol 36:99\u2013107. https:\/\/doi.org\/10.1016\/j.annonc.2024.09.002","journal-title":"Ann Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04457-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04457-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04457-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:55:55Z","timestamp":1787874955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04457-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":12,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4457"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04457-1","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Piotr Rutkowski has received honoraria for lectures and Advisory Boards from MSD, Bristol Myers Squibb, Pierre Fabre, Genesis Pharma and Medison Pharma outside of the scope of the study. Dariusz M. Kowalski is an advisory board member and a consultant for Amgen, BeONE, Bristol Myers Squibb, Daiichi-Sankyo, Johnson & Johnson, Medison MERCK, MSD, Pierre-Fabre, Pfizer, Roche, and Takeda. Victor Moreno has received consulting fees from Abbvie, Affimed, Astra Zeneca, Bayer, Bristol Myers Squibb, Ellipses Pharma., Janssen, Merck, Miltenyi, Pan-Cancer T, Pharmamar, Roche, Syneos, and ViroFend; and is a principal Investigator (institutional funding) from Abalos Therapeutics, AbbVie, Accesion Therapeutics, Adaptimmune, Alentis Therapeutics AG, Alterome Therapeutics, Amal Therapeutics, Amgen, ArtiOS Pharma, Ascendis Pharma, Astellas Pharma, AstraZeneca, Bayer, BeiGene, Bicycle Therapeutics, BioInvent, BioNTech, Bristol Myers Squibb, Boehringer Ingelheim, Captor Therapeutics, Celgene, Corbus Pharmaceuticals, Crinetics Pharmaceuticals, Cullinan MICA, Daiichi Sankyo, Debiopharm, Egle Therapeutics, Eikon Therapeutics, Exelixis, Exscientia, F-Star Beta Limited, Genentech, Genmab, Gilead, Gilead Sciences, GlaxoSmithKline, Grey Wolf Therapeutics, Hexal AG & Sandoz, IGI Therapeutics SA, ImCheck Therapeutics, Immunocore, Immutep, Incyte, iOMX Therapeutics, Ipsen Pharma, I.R.I.S., I.R.I.S. Servier, Italfarmaco, Janssen, Kumquat BioSciences, Light Chain Bioscience, Lilly, Loxo Oncology, Marengo Therapeutics, Medicenna, Medicenna Therapeutics, MediLink Therapeutics, Merck, Merus, Miltenyi Biomedicine, MOMA Therapeutics, MonTa Biosciences, MSD, NEC Bio Therapeutics, Ningbo Newbay, Novartis, Nurix Therapeutics, One Carbon Therapeutics, Oxford Biotherapeutics, Pfizer, PharmaMar, PMV Pharma, Pyxis Oncology, Regeneron, Relay Therapeutics, Revolution Medicines, Roche, Sanofi, Schr\u00f6dinger, Scorpion Therapeutics, Shattuck Labs, SystImmune, Tango Therapeutics, Tesaro, TheRas BridgeBio, Totus Medicines, Turning Point Therapeutics, and Vividion Therapeutics; and received research funding from AstraZeneca, Intheos, PMV Pharma, and Quironsalud. Aitana Calvo has received consulting fees or is an advisory board member from AstraZeneca, Bristol Myers Squibb, Daiichi, MSD, and Novartis. Fiona Thistlethwaite has received consulting fees from AstraZeneca, Grey Wolf Therapeutics, Immatics, OncoBayes, T-Knife Therapeutics, Waypoint; and is Principal Investigator (has received institutional funding) from Achilles Ltd, Adaptimmune, Amgen, Biontech, Bristol Myers Squibb, Chugai, Corbus, Crescendo Biologics, GenMab, Grey Wolf Therapeutics, Glaxo SmithKline, Immunocore, Incyte, Iovance, Janssen, Kymab Ltd\/Sanofi, Leucid, Moderna, Novalgen, Nucana, Oxford Vacmedix, Roche, RS Oncology LLC, Seagen, Takeda, T-Knife, UCB, Zymeworks. Ruth Plummer has received consulting fees from, Astex Therapeutics, Benevolent AI, Bristol Myers Squibb, Cybrexa Therapeutics, Ellipses, Genmab, Immunocore, Incyte, MSD, Nerviano, Novartis, and Sanofi Aventis, and for working as an IDMC member for Alligator Biosciences, AstraZeneca GlaxoSmithKline, Onxeo, Pharmamar, and SOTIO Biotech AG (all outside scope of study). Douglas Steinbach, John Loffredo, Sydney Akapame, Daniel Jonathan, Vinod Philip, Angela Girvin, Shalaka Hampras, and Peter Hellemans are employees and stockholders of Johnson & Johnson. Iurie Bulat has no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients or their legally designated representatives provided their written consent to participate in the study after having been informed about the nature and purpose of the study, Participation\/termination conditions, and risks and benefits of treatment.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"219"}}